NCT06168032View on ClinicalTrials.gov

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

NARecruitingINTERVENTIONAL
Enrollment

1,224

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

December 8, 2026

Study Completion Date

December 8, 2026

Conditions
COVID-19 RecurrentLung CancerVaccinationAntibodyChemotherapyImmune Checkpoint Inhibitor
Interventions
BIOLOGICAL

Any Chinese government-recommended COVID-19 booster vaccine

Any Chinese government-recommended COVID-19 booster vaccine(such as Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) and so on) will be once administered in the sixth month after COVID19 infection.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER